May 14, 2020
Oncopeptides Announces New Clinical and Preclinical Melflufen Data at the Upcoming European Hematology Association Meeting
May 13, 2020
Janssen's BCMA CAR-T Therapy JNJ-4528 Showed Early, Deep and Durable Responses in Heavily Pretreated Patients with Multiple Myeloma
May 13, 2020
Amgen Showcases Oncology Pipeline At ASCO 2020
May 05, 2020
Antengene Announces Expansion of Partnership with Karyopharm in Asia Pacific Markets
May 01, 2020
Halozyme Announces Janssen Receives FDA Approval Of DARZALEX FASPRO(TM) Utilizing Halozyme's ENHANZE® Technology For The Treatment Of Patients With Multiple Myeloma
Mar 25, 2020
Juntendo University Research: A New Combination Therapy is Effective in Treating a Rare Blood Cancer Cell Type
Mar 20, 2020
Oncopeptides Provides Update Regarding COVID-19 Impact on the Melflufen Clinical Program
Feb 10, 2020
Janssen Announces Submission to U.S. FDA for New DARZALEX® (Daratumumab)-Based Combination Regimen for Patients with Relapsed/Refractory Multiple Myeloma
Feb 03, 2020
GSK announces European Medicines Agency (EMA) accepted marketing authorisation application for belantamab mafodotin for the treatment of relapsed or refractory multiple myeloma
Dec 16, 2019
Pivotal DREAMM-2 study demonstrated a clinically meaningful overall response rate with belantamab mafodotin (GSK2857916) for patients with relapsed/refractory multiple myeloma
Nov 06, 2019
Oncopeptides to Highlight Data From Melflufen Clinical Program in Multiple Myeloma and AL Amyloidosis in Six Presentations at ASH Annual Meeting 2019
Sep 12, 2019
Amgen Highlights New Data From KYPROLIS® (carfilzomib) And Oncology Pipeline At IMW 2019
Jun 24, 2019
AbbVie Announces US FDA Lifts Partial Clinical Hold on Phase 3 Study of Venetoclax in Patients with Multiple Myeloma Positive for the t(11;14) Genetic Abnormality
Jun 14, 2019
New Data Presented at 24th EHA Congress From Oncopeptides' Phase 1/2 ANCHOR Trial Evaluating Melflufen in Relapsed/Refractory Multiple Myeloma (RRMM)
May 16, 2019
Oncopeptides Announces Acceptance of Four Abstracts Highlighting Melflufen Clinical Programs for Presentation at 24th EHA Congress in June 2019
Mar 12, 2019
Secura Bio Acquires Global Rights To Farydak®
Feb 27, 2019
Data From Oncopeptides Clinical Trials HORIZON and ANCHOR Evaluating Melflufen in RRMM Selected for Presentation at the AACR Annual Meeting
Feb 12, 2019
U.S. FDA Approves DARZALEX® (daratumumab) Split-Dosing Regimen
Dec 02, 2018
Oncopeptides Presents First Interim Data From the Ongoing Combination Trial ANCHOR With Melflufen at the 60th American Society of Hematology Meeting
Nov 01, 2018
Oncopeptides to Present Updated Data From the Two Ongoing Trials ANCHOR and HORIZON in Patients with RRMM at ASH in December 2018